调解分析将心脏代谢因素和肝脂肪与白质过强度和认知表现联系起来:英国生物库研究
Daniel E Askeland-Gjerde1,2, Lars T Westlye1,3,4, Patrik Andersson5
1Section for Precision Psychiatry, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Biological psychiatry global open science
|May 7, 2025
概括
非酒精性脂肪肝疾病与脑血管疾病和认知能力下降有关. 肝脂肪调解了心脏代谢风险因素和白质过强度之间的关系,这反过来影响了认知表现.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 肝病学 肝病学是一种肝病学.
- 放射学 放射学是一门学科.
背景情况:
- 非酒精性脂肪肝 (NAFLD) 与心脏代谢疾病,脑血管疾病和痴呆症有关.
- 脑血管疾病,特别是MRI上可见的白质超强度 (WMHs),是痴呆的常见原因.
- 肝脂肪在心脏代谢风险,WMH和认知功能之间的相互作用中的确切作用尚不清楚.
研究的目的:
- 研究心脏代谢因素,肝脂肪,WMH和认知表现之间的关联.
- 确定肝脂肪是否调解心脏代谢因素和WMHs之间的关系.
- 为了检查WMH是否调解肝脂肪和认知表现之间的关系.
主要方法:
- 利用了来自英国生物库队列 (N=32,461) 的数据,平均随访时间为9.3年.
- 采用线性回归来评估基线心脏代谢因子与肝脂肪,WMHs和认知表现的随访测量之间的关联.
- 应用结构方程建模,探索涉及肝脂肪和WMHs的调解途径.
主要成果:
- 几乎所有心脏代谢因素都与肝脏脂肪和WMHs显著相关.
- 肝脂肪与WMHs (r=0.11) 和认知表现 (r=-0.03) 有显著的关联.
- 肝脂肪调解了心脏代谢因素和WMH之间的关联,而WMH则调解了肝脂肪和认知表现之间的关联.
结论:
- 肝脏脂肪在从心脏代谢因素到脑血管疾病 (WMHs) 的途径中起着调解作用.
- 白质高强度会调解肝脂肪对认知表现的影响.
- 针对肝脏脂肪可能对预防与血管因素相关的认知障碍至关重要.
更多相关视频
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
737
05:34A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
Published on: November 22, 2024
307
相关概念视频
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
